Minerva Neurosciences Inc
Closed
3.98 -7.01
Overview
Share price change
24h
Min
4.27
Max
4.6899999999999995
Income | 158M -125M |
|---|---|
P/E Sector Avg | 2.462 60.549 |
EPS | -0.36 |
Employees | 7 |
Recommendations | Buy |
|---|---|
12 Months Forecast | +145.9% upside |
Next Earnings | 12 Aug 2026 |
|---|
Market Cap | 11M 196M |
|---|---|
Previous open | 10.99 |
Previous close | 3.98 |
Minerva Neurosciences Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Minerva Neurosciences Inc Forecast
Price Target
By TipRanks
145.9% upside
12 Months Forecast
Average 10.5 USD 145.9%
High 14 USD
Low 7 USD
Based on 2 Wall Street analysts offering 12 month price targets forMinerva Neurosciences Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Pre-tax profit
Sales
Interest expense on debt
Operating profit
$
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.